SEC Comment Letter for CymaBay Therapeutics, Inc. (CIK 0001042074) — Jul 8, 2020
CymaBay Therapeutics, Inc. (CIK 0001042074)
Date: July 8, 2020 · CIK: 0001042074 · Accession: 0000000000-20-006119
AI Filing Summary & Sentiment
File numbers found in text: 333-239670
Letter
United States securities and exchange commission logo July 8, 2020 Sujal Shah Chief Executive Officer CymaBay Therapeutics, Inc. 7575 Gateway Blvd, Suite 110 Newark, CA 94560 Re:CymaBay Therapeutics, Inc. Registration Statement on Form S-3 Filed July 2, 2020 File No. 333-239670 Dear Mr. Shah: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew B. Hemington, Esq.
Show Raw Text
United States securities and exchange commission logo
July 8, 2020
Sujal Shah
Chief Executive Officer
CymaBay Therapeutics, Inc.
7575 Gateway Blvd, Suite 110
Newark, CA 94560
Re:CymaBay Therapeutics, Inc.
Registration Statement on Form S-3
Filed July 2, 2020
File No. 333-239670
Dear Mr. Shah:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew B. Hemington, Esq.